DeepUll, a Metrix Partners client, signed a €20M venture loan with the European Investment Bank (EIB) in December 2022. The loan finances research, development and innovation for DeepUll’s culture-free diagnostics platform for the early identification of sepsis and other acute infections.

About DeepUll
DeepUll is a Barcelona medical diagnostics company founded in 2020 by the team behind STAT-Dx, which was sold to QIAGEN in 2018. It is developing an automated, easy-to-use device that identifies pathogens directly from a blood sample, without the culture step that slows down current testing.
Sepsis requires fast treatment. Standard blood cultures can take days to identify the pathogen, so doctors often start with broad-spectrum antibiotics. Faster, affordable diagnosis supports earlier targeted treatment and better use of antibiotics, which also helps fight antimicrobial resistance.
The EIB loan
The EIB announcement describes the financing as support for DeepUll’s research, development and innovation activities to accelerate and improve the diagnosis of sepsis. The deal was also reported by GenomeWeb.
The EIB’s venture debt product is designed for innovative European companies that have raised equity from venture investors and need additional long-term capital. It usually combines a loan with a performance-linked return, such as warrants or a royalty-like payment, instead of a high fixed interest rate.
How venture debt complements equity
The loan came shortly after DeepUll’s Series B, which later grew to €17M with Sabadell Asabys. Together, equity and EIB debt fund development through to regulatory and commercial milestones. For founders and existing investors, debt reduces dilution compared with raising the same amount in equity.
Five lessons on venture debt for life sciences
- Raise debt after equity. Lenders want a strong equity base and committed investors. Venture debt extends runway; it does not replace equity.
- Understand the full cost. Interest, fees and performance-linked payments together determine the real cost of the loan.
- Model the repayment. Grace periods give time to reach milestones. The plan must show how the company will repay or refinance.
- Read the covenants. Information rights, restrictions on further debt and change-of-control clauses affect future rounds and exits.
- Use public lenders’ credibility. An EIB loan follows detailed technical and financial review, which reassures later investors.
What founders should prepare for a venture debt process
- Audited accounts and monthly management accounts reconciled to them.
- A multi-year financial model with milestones, cash needs and repayment schedule.
- Details of all equity rounds and investor commitments.
- A technical plan showing how the loan will be used.
- Evidence of the clinical and market need.
Reporting after the loan
Public lenders require regular reporting on use of funds, project progress and financial position. Companies with several funders, such as venture investors, CDTI and the EIB, need one reconciled data set that feeds each report. Setting this up at the start avoids conflicting figures and saves management time throughout the life of the loan.
Metrix Partners in life sciences
Metrix supports life sciences companies with financing, reporting and fundraising. Other clients include Zymvol and VB Devices. Metrix also works on non-dilutive funding for deep tech and life sciences, as described in our practice in deep tech.






